HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy

Clinical Infectious Diseases

Volumn 59, Issue 9, 2014, Pages 1312-1321

  Besson, Guillaume J ^a   Lalama, Christina M ^b   Bosch, Ronald J ^b   Gandhi, Rajesh T ^c   Bedison, Margaret A ^a   Aga, Evgenia ^b   Riddler, Sharon A ^a   McMahon, Deborah K ^a   Hong, Feiyu ^a   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antiretroviral therapy; HIV 1 DNA decay; HIV 1 persistence; immune activation

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS 1 DNA; HUMAN IMMUNODEFICIENCY VIRUS 1 RNA; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DYNAMICS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MONONUCLEAR CELL; PLASMA; POLYMERASE CHAIN REACTION; VIREMIA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIV INFECTIONS; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; STATISTICAL MODEL; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; VIRAL LOAD; VIREMIA; YOUNG ADULT;

EID: 84913538191     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu585     Document Type: Article

References (42)

1. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-22.
2. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
3. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
4. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-6.
5. Koelsch KK, Liu L, Haubrich R, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411-9.
6. Murray JM, McBride K, Boesecke C, et al. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 2012; 26:543-50.
7. Steel A, John L, Shamji MH, et al. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. HIV Med 2008; 9:118-25.
8. Hatano H. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr Opin HIV AIDS 2013; 8:211-6.
9. Poizot-Martin I, Faucher O, Obry-Roguet V, et al. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol 2013; 57:351-5.
10. Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 2008; 9:269-82.
11. Cillo AR, Krishnan A, Mitsuyasu RT, et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr 2013; 63:438-41.
12. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59:229-35.
13. Malnati MS, Scarlatti G, Gatto F, et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc 2008; 3:1240-8.
14. Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline-and treatmentrelated factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-34.
15. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 68:1169-78.
16. von Wyl V, Gianella S, Fischer M, et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One 2011; 6:e27463.
17. Sharkey M, Triques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005; 79:5203-10.
18. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med 2010; 16:460-5.
19. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-61.
20. Coffin J, Swanstrom R. HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb Perspect Med 2013; 3:a012526.
21. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106:9403-8.
22. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
23. Hatano H, Scherzer R, Wu Y, et al. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr 2012; 61:317-25.
24. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-9.
25. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T-cells. J Virol 2006; 80:6441-57.
26. Bacchus C, Cheret A, Avettand-Fenoel V, et al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One 2013; 8:e64219.
27. Buzon MJ, Codoner FM, Frost SD, et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog 2011; 7:e1002314.
28. Wagner TA, McKernan JL, Tobin NH, Tapia KA, Mullins JI, Frenkel LM. An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells. J Virol 2013; 87:1770-8.
29. Maldarelli F, Kearney M, Palmer S, et al. HIV populations are large and accumulate high genetic diversity in nonlinear fashion. J Virol 2013; 87:10313-23.
30. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 76:4138-44.
31. Morlese J, Teo IA, Choi JW, Gazzard B, Shaunak S. Identification of two mutually exclusive groups after long-term monitoring of HIV-1 DNA 2-LTR circle copy number in patients on HAART. AIDS 2003; 17:679-83.
32. Pace MJ, Graf EH, O'Doherty U. HIV 2-long terminal repeat circular DNA is stable in primary CD4+ T-cells. Virology 2013; 441:18-21.
33. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714-20.
34. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-88.
35. Fourati S, Lambert-Niclot S, Soulie C, et al. HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother 2012; 67:2323-6.
36. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9: e1003174.
37. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T-cells. PLoS Pathog 2006; 2:e68.
38. Bouchat S, Gatot JS, Kabeya K, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T-cells from HIV-1-infected HAART-treated patients. AIDS 2012; 26:1473-82.
39. Wang Y, Whittall T, Rahman D, et al. The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques. PLoS One 2012; 7:e34433.
40. Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology 2013; 10:11.
41. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81:2508-18.
42. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.